Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

30%

3 trials in Phase 3/4

Results Transparency

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

2(33.3%)

Phase 2

1(16.7%)

N/A

1(16.7%)

Phase 4

1(16.7%)

Phase 1

1(16.7%)

6Total

Phase 3(2)

Phase 2(1)

N/A(1)

Phase 4(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07020377Phase 1Active Not Recruiting

Dapagliflozin in Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus Patients (T2DM).

Role: collaborator

NCT06499675Completed

Prevalence of Steatosis and Steatohepatitis in Patients Undergoing Bariatric Surgery; a Biopsy-based Study

Role: lead

NCT06325826Active Not Recruiting

The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs

Role: lead

NCT03884062Completed

Clinical Impacts of Achieving SVR in Patients With Advanced Hepatic Fibrosis Related to Chronic HCV Treated With Direct Acting Antivirals

Role: lead

NCT04177043Phase 4Completed

Model Towards Elimination of Hepatitis C Infection in Egypt: Feasibility and Effectiveness in 73 Villages

Role: lead

NCT04173520Completed

ELRIAH Score: A Simple Score for HCC Risk Stratification in CHC Patients With Cirrhosis or Advanced Liver Fibrosis Who Achieved SVR Following DAA Therapy

Role: lead

NCT03343444Phase 3Unknown

Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents

Role: lead

NCT03415334Not ApplicableCompleted

Effect of Implementation Of Outreach Behavioral Change Program for HCV Elimination

Role: collaborator

NCT03186313Phase 3Completed

A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection

Role: lead

NCT02483156Phase 2Completed

Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection

Role: lead

All 10 trials loaded